Loading

Please wait...

Zerbaxa

Generic Name: ceftolozane and tazobactam (sef TOL oh zane and TAZ oh BAK tam)
Brand Name: Zerbaxa
Physician reviewed Zerbaxa patient information - includes Zerbaxa description, dosage and directions.
  • Prescription Settings
  • X

Prices and coupons of Zerbaxa

Set your location
for drug prices near you

Enter your zip code

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Zerbaxa is a combination antibiotic that is used to treat certain bacterial infections of the lungs, stomach, or urinary tract. Zerbaxa is sometimes given in combination with another antibiotic medicine. Zerbaxa may also be used for purposes not listed in this medication guide. Follow all directions on your medicine label and package. Tell each of your healthcare prOviders about all your medical conditions, allergies, and all medicines you use. You should not use Zerbaxa if you are allergic to ceftolozane or tazobactam, or if you are allergic to similar antibiotics, such as: Learn more

Zerbaxa Side Effects

Zerbaxa Side Effects

Note: This document contains side effect information about ceftolozane / tazobactam. Some of the dosage forms listed on this page may not apply to the brand name Zerbaxa.

For the Consumer

Applies to ceftolozane / tazobactam: intravenous powder for solution, powder iv (infusion)

Along with its needed effects, ceftolozane / tazobactam may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking ceftolozane / tazobactam:

More common

  • Fever

Less common

  • Blurred vision
  • confusion
  • convulsions
  • decreased urine
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • dry mouth
  • increased thirst
  • irregular heartbeat
  • loss of appetite
  • muscle pain or cramps
  • nausea or vomiting
  • numbness or tingling in the hands, feet, or lips
  • pale skin
  • rash
  • sweating
  • troubled breathing with exertion
  • unusual bleeding or bruising
  • unusual tiredness or weakness

Rare

  • Abdominal or stomach cramps or pain
  • arm, back, or jaw pain
  • bloating
  • bloody urine
  • chest pain or discomfort
  • chest tightness or heaviness
  • constipation
  • creamy white, curd-like patches in the mouth or throat
  • decreased frequency or amount of urine
  • diarrhea
  • dry, red, hot, or irritated skin
  • fast or irregular heartbeat
  • hives or welts, itching skin
  • increased thirst
  • lower back or side pain
  • pain when eating or swallowing
  • severe constipation
  • severe vomiting
  • swelling of the face, fingers, or lower legs
  • weight gain

Incidence not known

  • Abdominal or stomach tenderness
  • cough
  • difficulty with swallowing
  • dizziness
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • severe abdominal or stomach cramps and pain
  • watery and severe diarrhea, which may also be bloody

Some side effects of ceftolozane / tazobactam may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Headache

Less common

  • Acid or sour stomach
  • belching
  • burning feeling in the chest or stomach
  • fear or nervousness
  • heartburn
  • indigestion
  • stomach discomfort or upset
  • trouble sleeping

Rare

  • Flushed, dry skin
  • fruit-like breath odor
  • increased hunger
  • increased urination
  • unexplained weight loss

For Healthcare Professionals

Applies to ceftolozane / tazobactam: intravenous powder for injection

General

In clinical studies of complicated intraabdominal infections (cIAI) and complicated urinary tract infections (cUTI), the most common side effects were nausea, diarrhea, headache, constipation, and pyrexia.

In a clinical study for hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP), side effects reported in at least 2% of patients included increased hepatic transaminase, renal impairment/renal failure, diarrhea, intracranial hemorrhage, vomiting, and Clostridium difficile colitis.

Hematologic

In cIAI and cUTI clinical studies, seroconversion to positive direct Coombs test was reported in 0.2% of patients using this drug (0% in patients using the comparator). In the HABP/VABP clinical study, seroconversion to positive direct Coombs test was reported in 31.2% of patients using this drug (3.6% in patients using meropenem). In clinical studies, hemolysis was not reported in patients who developed a positive direct Coombs test (in any treatment group).

Very common (10% or more): Positive direct Coombs test (up to 31.2%)

Common (1% to 10%): Anemia, thrombocytosis

Hepatic

Very common (10% or more): Increased hepatic transaminase (up to 11.9%; included increased ALT, increased AST, increased hepatic enzyme, hypertransaminasemia, abnormal liver function test)

Common (1% to 10%): Increased ALT, increased AST

Uncommon (0.1% to 1%): Increased serum GGT

Renal

Common (1% to 10%): Renal impairment/renal failure (included acute renal failure, anuria, azotemia, oliguria, prerenal failure, renal failure, renal impairment)

Gastrointestinal

Common (1% to 10%): Nausea, diarrhea, constipation, vomiting, abdominal pain, C difficile colitis (included C difficile colitis, C difficile infection, Clostridium test positive)

Uncommon (0.1% to 1%): Paralytic ileus, gastritis, abdominal distension, dyspepsia, flatulence, oropharyngeal candidiasis

Frequency not reported: C difficile-associated diarrhea

Nervous system

Common (1% to 10%): Headache, dizziness, intracranial hemorrhage (included cerebellar hemorrhage, cerebral hematoma, cerebral hemorrhage, intracranial hemorrhage, hemorrhagic stroke, hemorrhagic transformation stroke intraventricular hemorrhage, subarachnoid hemorrhage, subdural hematoma)

Uncommon (0.1% to 1%): Ischemic stroke

Other

In phase 2 and 3 cIAI trials, death occurred in 14 of 564 patients using this drug and 8 of 536 patients using meropenem; causes of death varied and included worsening and/or complications of infection, surgery, and underlying conditions.

Common (1% to 10%): Pyrexia, increased mortality

Uncommon (0.1% to 1%): Increased serum alkaline phosphatase, candidiasis

Psychiatric

Common (1 to 10%): Insomnia, anxiety

Metabolic

Common (1% to 10%): Hypokalemia

Uncommon (0.1% to 1%): Hyperglycemia, hypomagnesemia, hypophosphatemia

Cardiovascular

Common (1% to 10%): Hypotension, atrial fibrillation

Uncommon (0.1% to 1%): Tachycardia, angina pectoris, venous thrombosis, phlebitis

Dermatologic

Common (1% to 10%): Rash

Uncommon (0.1% to 1%): Urticaria

Local

Common (1% to 10%): Infusion site reactions

Respiratory

Uncommon (0.1% to 1%): Dyspnea

Genitourinary

Uncommon (0.1% to 1%): Vulvovaginal candidiasis, fungal urinary tract infection

Hypersensitivity

Frequency not reported: Hypersensitivity reactions

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Zerbaxa (www.drugs.com/mtm/zerbaxa.html).